Mallinckrodt Pharmaceuticals A.I CyberSecurity Scoring
28/02/2026
Access Monitoring Plan
Access Monitoring Plan
No incidents recorded for Mallinckrodt Pharmaceuticals in 2026.
No incidents recorded for Mallinckrodt Pharmaceuticals in 2026.
No incidents recorded for Mallinckrodt Pharmaceuticals in 2026.
Established in 1907, Alembic Pharmaceuticals Limited is a leading pharmaceutical company in India. The Company is vertically integrated with the ability to develop, manufacture and market pharmaceutical products, pharmaceutical substances and Intermediates. Alembic is the market leader in the Macrolides segment of anti-infective drugs in India. Alembic's manufacturing facilities are located in Vadodara and Baddi in Himachal Pradesh. The plant at Vadodara has the largest fermentation capacity in India. The Panelav facility houses the API and formulation manufacturing (both US FDA approved) plants. The plant at Baddi, Himachal Pradesh manufactures formulations for the domestic and non-regulated export market. The company has a state of the art Research Centre at Vadodara.
The Zydus Group with an overarching purpose of empowering people with freedom to live healthier and more fulfilled lives, is an innovative, global life-sciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies. The group employs over 27000 people worldwide and is driven by its mission to unlock new possibilities in life-sciences through quality healthcare solutions that impact lives. The group aspires to transform lives through pathbreaking discoveries.
A vertically integrated, Global Pharmaceutical Company. Established in 1989, we are engaged in developing, manufacturing, and marketing a wide range of formulations across several major therapeutic areas including anti-infectives, cardiovascular, anti-diabetic, dermatology, and hormone treatment. We develop, manufacture, and globally distribute a broad range of pharmaceutical products across therapies in multiple dosage forms such as solid orals, liquid orals, topical formulations, injectables (Dry Powder) metered dose inhalers and dry powder inhalers. Our Vision To be a leading global pharmaceutical company by providing high quality, affordable and innovative therapeutic solutions for patients with diverse medical needs. Our Mission To contribute towards improving patients’ quality of life across the globe, by providing effective and accessible medicines.
Established in 1966, PT Kalbe Farma Tbk. (“the Company” or “Kalbe”) has gone a long way from its humble beginnings as a garage-operated pharmaceutical business in North Jakarta. It has expanded by strategic acquisitions of pharmaceutical companies, building a leading brand positioning and reaching to international markets to transform itself into an integrated consumer health and nutrition enterprise to promote its mission to improve health for a better life. Kalbe expands its business interests and transformed itself to become a provider of an integrated healthcare solution through its 4 business divisions: the Prescription Pharmaceutical Division, Consumer Health Division, Nutritionals Division and Distribution and Logistics Division. These business divisions manage an extensive portfolio of prescription pharmaceuticals and OTC drugs, energy drink and nutrition products, as well as a robust distribution arm serving over one million outlets across Indonesia’s vast archipelago. In the international market, the Company has established its footprint in ASEAN countries, Nigeria, and South Africa, positioning Kalbe as a national pharmaceutical company with a competitive edge in the export market. Kalbe Farma has established a robust research and development activities in leading edge generic drug formulation and continuous development of innovative consumer and nutritional products. Through strategic alliances with international partners, Kalbe have also started to support several successful research and development venture working on cancer drugs, stem cells and biotechnology research. With 17,000 employees, Kalbe Farma is the largest healthcare provider in Indonesia, with unrivaled marketing, branding, distribution, financial strength and research and development expertise. Kalbe Farma is also the largest publicly-listed pharmaceutical company in Southeast Asia, commanding a market capitalization of Rp71.0 trillion and sales turnover Rp21.0 trillion by end of 2018.
At UCB, we believe everyone deserves to live the best life they can - as free as possible from the challenges and uncertainty of disease. Our purpose is to support people living with severe central nervous system and immunological conditions by delivering meaningful solutions that go beyond medicine. We are driven by the experiences of patients and caregivers, and inspired to pursue innovations that create real value - not just in clinical outcomes, but in everyday moments, dreams pursued, and simple pleasures enjoyed. Our ambition is to unlock transformative science and technologies that respond to unmet needs and elevate lives. From our headquarters in Belgium to nearly 40 countries around the world, we nurture a culture of respect and care. By listening deeply and collaborating across borders and disciplines, we enable cutting-edge research shaped by patients’ needs. Through strong connections with healthcare professionals, partners, and communities, we strive to make a lasting impact - today and into the future. We're inspired by patients, driven by science.
The world’s leading animal health company. We’ve been innovating ways to predict, prevent, detect, and treat animal illness for over 70 years, and we continue to stand by those raising and caring for animals worldwide – from veterinarians and pet owners to livestock farmers. Our leading portfolio and pipeline makes a difference in over 100 countries. Community Guidelines: This page is intended to share how Zoetis is advancing care for animals. We aspire to create a supportive community, but there are guidelines to which posts and comments on this page must adhere. If your post references a side effect related to any Zoetis product, we may contact you for more information. To monitor the safety of Zoetis products, we advise you to call our Veterinary Medical Information and Product Support Team at 1-888-963-8471; Support Team is available Mon-Fri 9am to 6:30pm ET. We reserve the right to remove any post/comment that violates LinkedIn Guidelines. As a last resort, we reserve the right to block users that demonstrate a repeated pattern of violating LinkedIn’s spirit of constructive, professional discourse. We respectfully request that you refrain from posting comments including: Unsolicited and/or unverified medical advice Vulgarity and/or profanity Discriminatory and/or derogatory comments, hate speech Politics and religion Personal attacks and/or threats Promotion of illegal activity Copyright/trademark infringements Topics that may be considered spam/advertising Our regular business hours are Mon-Fri 9am to 5pm ET. Zoetis does not endorse and is not responsible for information and opinions shared by community members. The information shared is provided for educational purposes only and is not intended to replace discussions with an animal healthcare professional. Testimonials represent individual experience only and the experiences and opinions of community members may be unique to the speaker. Terms of Use: https://www.zoetis.com/terms-of-use
At Merck, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world – and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities. For more information, visit www.merck.com. This site is intended for residents of the United States and Canada and their territories only. FLS: http://merck.us/3TKXNuZ
At Johnson & Johnson Innovative Medicine, we innovate with purpose, to lead where medicine is going. The experiences of patients around the world inform and inspire our science-based innovations, which continue to change and save lives. Applying rigorous science with compassion, we confidently address the most complex diseases of our time and develop the potential medicines of tomorrow. We are continuously working to develop treatments, aspiring to find cures, pioneering the path from lab to life, and championing patients every step of the way. https://bit.ly/3reuMvK
Championing the missions that matter™. Catalent, Inc. is a leading global contract development and manufacturing organization (CDMO) and trusted partner to pharma, biotech, and consumer health companies worldwide. We put patients first in everything we do, helping people live better and healthier lives through every product we help develop, manufacture and deliver. With over 1,000 active development programs at any given time, we launch over 100 new products and line extensions annually. Catalent has supported half of all FDA approvals over the past decade, and our teams working at over 40 global sites help us produce over 60 billion doses every year. Our strength lies in our people: teams across our more than 40 sites and thousands of passionate scientists and technicians who bring expertise in development sciences, delivery technologies, and multi-modality manufacturing. What unites us is our commitment to championing our partners’ missions as our own, anticipating customer needs, solving complex challenges and ultimately making a difference in the lives of patients across the globe. At Catalent, you will be able to directly have an impact, solving problems and ensuring excellence for our customers. Our focus on delivering meaningful outcomes alongside our customers means your work directly impacts millions of people around the world. Join us in championing the missions that matter. Catalent is headquartered in Tampa, Florida, with over 40 global sites. Visit www.catalent.com to learn more.
Latest updates, reports, and threat intel affecting the global network.
A Delaware federal jury awarded Mallinckrodt Pharmaceuticals almost $9.5 million on Friday, finding that French industrial gas company...
Endo's shareholders will receive $80 million in cash and own 49.9% of the combined company for a pro forma enterprise deal value of $6.7 billion.
Mallinckrodt Pharmaceuticals and Endo have agreed to merge in a $6.7bn deal, combining two pharmaceutical companies that recently emerged from bankruptcy...
Mallinckrodt and Endo , drugmakers which recently emerged from bankruptcy after a wave of U.S. opioid lawsuits, announced plans Thursday to...
Mallinckrodt and Endo, drugmakers with a shared history of bankruptcy and US opioid litigation, will merge in a deal valued at nearly $7 billion.
Mallinckrodt Pharmaceuticals and Endo have agreed to combine in a nearly $7bn deal after the pair emerged from bankruptcy processes linked to liabilities over...
Mallinckrodt and Endo are exploring a potential merger that could be valued at about $7 billion, person familiar with the matter told...
PRNewswire/ -- Mallinckrodt plc ("Mallinckrodt" or the "Company"), a global specialty pharmaceutical company, today announced that it has...
Drugmaker Mallinckrodt on Tuesday won court approval for a bankruptcy plan that cuts $1 billion from what it must pay opioid crisis victims,...
Zephyr's HTTP server (subsys/net/lib/http) provides a static-filesystem resource type (HTTP_RESOURCE_TYPE_STATIC_FS, available when CONFIG_FILE_SYSTEM is enabled) that serves files from a configured root directory. Before this fix, both the HTTP/1 and HTTP/2 front-ends placed the raw, attacker-controlled request path into client-url_buffer (assembled in on_url() for HTTP/1 and copied verbatim from the :path pseudo-header for HTTP/2) without resolving ./.. segments. The static-FS handler then built the on-disk filename by directly concatenating the configured root with that raw URL (snprintk(fname, ..., "%s%s", static_fs_detail-fs_path, client-url_buffer) at http_server_http1.c:603 and http_server_http2.c:490) and opened it with fs_open(fname, FS_O_READ). Because the handler is reached via wildcard/leading-dir (fnmatch FNM_LEADING_DIR) or fallback resource matching, a request such as GET /<prefix/../../<file is dispatched to the handler and, after the underlying filesystem (e.g. LittleFS/FAT) resolves the .. segments, escapes the configured web root, letting an unauthenticated remote client read arbitrary readable files on the mounted volume (information disclosure). The HTTP server requires no TLS or authentication to reach this path. The fix adds http_server_remove_dot_segments(), which canonicalizes the path portion of the URL before resource lookup in both protocol handlers, neutralizing the traversal. Affects releases v4.0.0 through v4.4.0 for deployments that register a static-filesystem resource.
The IPv6 Neighbor Discovery handlers in subsys/net/ip/ipv6_nbr.c (handle_ra_input, handle_ns_input, handle_na_input) used an incorrect boolean expression that combined the RFC 4861 validity checks with the ICMPv6 code check using the wrong operator precedence: the form was '((length/hop/source/target checks) && (icmp_hdr-code != 0))'. Because every legitimate ND message carries ICMPv6 code 0, an attacker setting code == 0 (the normal value) caused the entire predicate to evaluate false, so the packet was never dropped and all of the other checks were silently skipped. The bypassed checks include the mandatory Hop Limit == 255 verification (which proves an ND packet originated on-link and was not forwarded) and, for Router Advertisements, the requirement that the source be a link-local address, as well as multicast-target sanity checks. As a result, an adjacent on-link attacker — and, because the Hop-Limit-255 guard is bypassed, potentially a remote/off-link attacker whose packets would otherwise be rejected — can have forged Router Advertisement, Neighbor Solicitation, and Neighbor Advertisement messages accepted. A forged RA lets the attacker reconfigure the victim's default router, on-link prefixes (SLAAC), MTU, reachable/retransmit timers, and (with CONFIG_NET_IPV6_RA_RDNSS) DNS servers, while forged NS/NA enable neighbor-cache poisoning, enabling man-in-the-middle, traffic redirection, and denial of service. The flaw is an input-validation/authentication weakness rather than a memory-safety issue: the underlying packet-parsing primitives (net_pkt_get_data, net_pkt_read, net_pkt_skip) are independently bounds-safe and the validated 'length' is the true buffer length, so skipping the length check causes no out-of-bounds access. The defect has existed since the logic was introduced in 2018 and shipped in all releases through v4.4.0; it is fixed by splitting the condition so any failing check drops the packet.
A heap buffer overflow in the HighPriorityASDUQueue_hasUnconfirmedIMessages function of lib60870 v2.3.3 to v2.3.6 allows attackers to cause a Denial of Service (DoS) via a crafted payload.
A heap buffer overflow in the TS7Worker::PerformFunctionWrite() function (/core/s7_server.cpp) of snap7 v1.4.3 allows attackers to cause a Denial of Service (DoS) via a crafted packet.
mcumgr_serial_process_frag() in subsys/mgmt/mcumgr/transport/src/serial_util.c calls net_buf_reset() on the result of smp_packet_alloc() before checking it for NULL. smp_packet_alloc() uses net_buf_alloc(K_NO_WAIT) against the shared MCUmgr packet pool (CONFIG_MCUMGR_TRANSPORT_NETBUF_COUNT, default 4), which returns NULL when the pool is exhausted. In default builds the __ASSERT_NO_MSG in net_buf_reset is a no-op, so net_buf_simple_reset writes through the NULL pointer (buf->len = 0; buf->data = buf->__buf), causing a fault/crash. The fragment data reaches this code from attacker-controlled bytes on the MCUmgr serial/UART/shell-console transports (smp_uart.c, smp_raw_uart.c, smp_shell.c), and a fresh buffer is allocated at the start of essentially every new packet. An attacker on the serial/console link can flood the transport to drive the 4-entry buffer pool to exhaustion and induce the NULL dereference, crashing the device (denial of service). The defect was introduced after the original MCUmgr rework and shipped in Zephyr v4.4.0. The fix moves the NULL check ahead of net_buf_reset.
curl -i -X GET 'https://api.rankiteo.com/underwriter-getcompany-history?
linkedin_id=axa' -H 'apikey: YOUR_API_KEY_HERE'
Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.
Rankiteo is a unified scoring and risk platform that analyzes billions of signals weekly to help organizations gain faster, more actionable insights into emerging threats. Empowering teams to outpace adversaries and reduce exposure.